Skip Navigation
Menu
Original Research |1 December 1975

Amikacin Therapy for Serious Gram-Negative Bacillary Infections

RICHARD D. MEYER, M.D.; ROBERT P. LEWIS, M.D.; E. DUANE CARMALT, M.D.; SYDNEY M. FINEGOLD, M.D., F.A.C.P.

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
Grant support: in part by a grant from Bristol Laboratories, Syracuse, New York.
This paper was presented in part at the Ninth International Congress of Chemotherapy, 15 July 1975, London, England, and at the 15th Interscience Conference on Antimicrobial Agents and Chemotherapy, 26 September 1975, Washington, D.C.
▸Requests for reprints should be addressed to Richard D. Meyer, M.D., Infectious Disease Section 111F, Wadsworth Hospital Center, Wilshire and Sawtelle Blvds., Los Angeles, CA 90073.
  • Los Angeles, California
×
FULL TEXT

Abstract

Amikacin is a new aminoglycoside antibiotic pharmacologically similar to kanamycin. It has a wide range of activity against Gram-negative bacilli, including many resistant to gentamicin. Thirty-six serious Gram-negative bacillary infections were treated with amikacin. Twenty-nine patients (80.6%) responded (cured or improved). Twelve of 13 patients with gentamicin-resistant pathogens responded. Minor ototoxicity occurred in 6 patients and was associated with prolonged therapy or previous aminoglycoside therapy. Possible nephrotoxicity with amikacin was found in 6 patients. Amikacin should be used primarily to treat suspected or known gentamicin-resistant pathogens.

FULL TEXT
PDF
Not Available
Citations
Citation

MEYER RD, LEWIS RP, CARMALT ED, FINEGOLD SM. Amikacin Therapy for Serious Gram-Negative Bacillary Infections. Ann Intern Med. 1975;83:790–800. doi: 10.7326/0003-4819-83-6-790

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 1975;83(6):790-800.

DOI: 10.7326/0003-4819-83-6-790

107 Citations

Related Articles
Efficacy and Toxicity of Single Daily Doses of Amikacin and Ceftriaxone versus Multiple Daily Doses of Amikacin and Ceftazidime for Infection in Patients with Cancer and Granulocytopenia
Annals of Internal Medicine; 119 (7_Part_1): 584-593
Treatment of Disseminated Mycobacterium avium Complex Infection in AIDS with Amikacin, Ethambutol, Rifampin, and Ciprofloxacin
Annals of Internal Medicine; 113 (5): 358-361
Drugs Five Years Later: Amikacin
Annals of Internal Medicine; 95 (3): 328-332
Massive Amikacin "Overdose"
Annals of Internal Medicine; 91 (2): 227-228
View MoreView Less

Related Topics
Infectious Disease

Infectious Disease.

PubMed Articles
Tailored nanocarriers for the pulmonary delivery of levofloxacin against Pseudomonas aeruginosa: a comparative study.
Mol Pharm 2019.
Clinical features and antimicrobial susceptibility profiles of culture-proven neonatal sepsis in a tertiary children's hospital, 2013 to 2017.
Medicine (Baltimore) 2019;98(12):e14686.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×